The relationship of pregnancy to the use of highly active antiretroviral therapy

American Journal of Obstetrics and Gynecology

Volumn 184, Issue 6, 2001, Pages 1221-1227

  Minkoff, Howard ^a   Ahdieh, Linda ^b   Watts, Heather ^c   Greenblatt, Ruth M ^d   Schmidt, Julie ^f   Schneider, Michael ^b   Stek, Alice ^e  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f Jr Hospital of Cook County   (United States)

Author keywords

CD4+ cell count; Highly active antiretroviral therapy; Human immunodeficiency virus; Human immunodeficiency virus type 1 ribonucleic acid; Pregnancy; Women

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TEST; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS LOAD;

EID: 0035340782     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.113871     Document Type: Article

References (22)

1. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-503.
2. Hogg RS, Heath K, Yip B, Craib KJ, O'Shaughnessy MV, Schetcher MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
4. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
5. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
7. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-9.
8. Gange SJ, Barron Y, Greenblatt R, Anastos K, Minkoff H, Young M, et al. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. In: Proceedings of the 1999 National Conference on Women and HIV/AIDS; 1999 Oct 9-12; Los Angeles, California. Los Angeles: The Conference; 1999.
9. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-20.
10. Clinical Guidelines for the Use of Zidovudine Therapy in Pregnancy to Reduce Perinatal Transmission of HIV Albany (NY): New York State Dept. of Health, AIDS Institute; 1994.
11. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention [published errata appear in MMWR Morb Mortal Wkly Rep 1998;47:287 and 1998;47:315]. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30.
12. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The women's interagency HIV study. WIHS Collaborative Study Group. Epidemiology 1998;9:117-25.
13. Revets H, Marissens D, de Wit S, Lacor P, Clumeck N, Lauwers S, et al. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996;34:1058-64.
14. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Dept. of Health and Human Services and Henry J. Kaiser Family Foundation [published erratum appears in MMWR Morb Mortal Wkly Rep 1998;47:619]. MMWR Morb Mortal Wkly Rep 1998;47(RR-5):43-82.
15. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
16. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1999;94:641-6.
17. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-7.
18. Fischer C, Rosenwald V, Harewood L, Blum C. Antiretrovirals during pregnancy in HIV-1-positive women in New York City [letter]. Lancet 1998;351:1029-30.
19. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatrie AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385-93.
20. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
21. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to nucleoside analogues. Lancet 1999;354:1084-9.
22. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89:1602-8.